sepsis

Mar 27, 2020

Gradientech Awarded $634K for Commercialization of AST Platform

The Swedish firms plans to launch clinical performance studies in support of getting CE marking for its QuickMIC system.

Mar 26, 2020

Biocartis, Immunexpress Ink Co-Commercialization Agreement for Sepsis Test

Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the US.

Mar 09, 2020

Ortho Clinical Diagnostics Procalcitonin Assay Receives FDA Clearance

The assay will be available on the Vitros 3600 Immunodiagnostic System, Vitros 5600 and Vitros XT 7600 Integrated Systems, and Vitros ECi/ECiQ Systems.

Mar 05, 2020

New Sepsis Test Uses Nanopore Sequencing to Detect Pathogens From Cell-Free DNA

Premium

The method uses nanopore sequencing to analyze short cell-free DNA fragments from blood, providing results in as little as six hours.

Mar 03, 2020

GenMark Diagnostics Begins Shipping SARS-CoV-2 Assay While Interest in BCID Panel Grows

Premium

GenMark announced on Monday that it has begun shipping its first research-use-only tests for the novel coronavirus and intends to seek emergency use authorization.

Mar 02, 2020

GenMark Diagnostics Q4 Revenues Rise 40 Percent

More than 70 percent of ePlex analyzer placements in the fourth quarter were within labs that previously had a competitive analyzer, the firm said.

Feb 29, 2020

Accelerate Diagnostics Advances New Sales and Marketing Approaches for Rapid Sepsis ID-AST Testing

Premium

As part of the new sales process the firm launched a return-on-investment tool that adapts data from existing customers to predict potential outcomes.

Feb 27, 2020

Accelerate Diagnostics Q4 Revenues Jump 94 Percent

The firm placed 137 commercially contracted instruments in the quarter and 304 in the full year 2019.

Feb 25, 2020

New T2 Biosystems CEO Plans to Shrink Costs, Sharpen Sales Strategy

Premium

Leadership aims to lower cost of goods and real estate footprint, while driving test utilization by targeting clinicians.

Feb 24, 2020

T2 Biosystems Q4 Revenues Jump 71 Percent, Miss Analyst Estimates

The firm placed 45 of its T2Dx diagnostics instruments in 2019, but plans to reduce that number in 2020 to focus on instrument utilization.

Menu

sepsis

Gradientech Awarded $634K for Commercialization of AST Platform

Biocartis, Immunexpress Ink Co-Commercialization Agreement for Sepsis Test

Ortho Clinical Diagnostics Procalcitonin Assay Receives FDA Clearance

New Sepsis Test Uses Nanopore Sequencing to Detect Pathogens From Cell-Free DNA

GenMark Diagnostics Begins Shipping SARS-CoV-2 Assay While Interest in BCID Panel Grows

GenMark Diagnostics Q4 Revenues Rise 40 Percent

Accelerate Diagnostics Advances New Sales and Marketing Approaches for Rapid Sepsis ID-AST Testing

Accelerate Diagnostics Q4 Revenues Jump 94 Percent

New T2 Biosystems CEO Plans to Shrink Costs, Sharpen Sales Strategy

T2 Biosystems Q4 Revenues Jump 71 Percent, Miss Analyst Estimates

Pages

Breaking News

Thermo Fisher Scientific Prices €1.2B Senior Notes Offering

US Justice Department Sues Anthem for Allegedly Submitting False Diagnosis Data to CMS

Rendu Biotechnology Gets Emergency Approval in China for Coronavirus Detection Kit

Myriad Genetics Seeks Japan Approval for Advanced Pancreatic, Prostate Cancer Companion Diagnostic

White House Wants Hospitals to Report Coronavirus Testing Data

Luminex Receives FDA Emergency Use Authorization for Coronavirus Multiplex Panel

What's Popular?

Gradientech Awarded $634K for Commercialization of AST Platform

Biocartis, Immunexpress Ink Co-Commercialization Agreement for Sepsis Test

Sponsorships